Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

10.99 -1.54 (-12.29%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

March 16, 2023

From Novocure

Via Business Wire

2 Stocks That Could Rebound and Rise 30% or More in 2023 ↗

March 10, 2023

They're down, but they aren't yet out.

Via The Motley Fool

2 Best Defensive Stocks to Buy in March ↗

March 08, 2023

These two defensive stocks should shine in the event of a marketwide correction.

Via The Motley Fool

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

March 01, 2023

From Novocure

Via Business Wire

NovoCure Earnings Perspective: Return On Capital Employed ↗

February 27, 2023

Via Benzinga

Why NovoCure Stock Is Falling Today ↗

February 23, 2023

Investors were looking for a stronger Q4 from the cancer company.

Via The Motley Fool

NovoCure (NVCR) Q4 2022 Earnings Call Transcript ↗

February 23, 2023

NVCR earnings call for the period ending December 31, 2022.

Via The Motley Fool

Why Novocure Stock Was so Healthy Today ↗

February 15, 2023

There was good news from the laboratory on Hump Day.

Via The Motley Fool

Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

March 01, 2023

From Novocure

Via Business Wire

Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

February 23, 2023

From Novocure

Via Business Wire

Allyson J. Ocean, M.D., Joins Novocure Board of Directors

February 23, 2023

From Novocure

Via Business Wire

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

February 15, 2023

From Novocure

Via Business Wire

Why Novocure Stock Is Sliding Today ↗

January 19, 2023

Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs.

Via The Motley Fool

Will Novocure Stock Sink or Soar in 2023? ↗

January 19, 2023

The stock has both soared and sank already this year.

Via The Motley Fool

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes ↗

January 19, 2023

A series of unexpected C-suite changes sent shares diving again.

Via Investor's Business Daily

Novocure Announces Organizational Changes to Prepare for Future Growth

January 19, 2023

From Novocure

Via Business Wire

Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace ↗

January 17, 2023

Shares have given back a chunk of their 69% single-day gain on a lung cancer study.

Via Investor's Business Daily

Why Novocure Stock Is Sinking Today ↗

January 09, 2023

The company provided a disappointing sneak peek at its Q4 results.

Via The Motley Fool

Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update

January 09, 2023

From Novocure

Via Business Wire

Why Novocure Stock Is Flying High ↗

January 06, 2023

Here's why Novocure stock popped over 68% on Jan. 5.

Via The Motley Fool

Is NovoCure a Good Stock to Buy Right Now? ↗

January 07, 2023

Successful clinical trial results recently pushed this stock more than 68% higher overnight -- but what about the road ahead?

Via The Motley Fool

Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review ↗

January 06, 2023

The major indexes rallied Friday on the jobs report and services data.

Via Investor's Business Daily

Tesla, Amazon, Aehr, Silvergate, Novocure: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

January 05, 2023

Major Wall Street indices closed over 1% lower on Thursday, dragged by strong employment data which could nudge the Federal Reserve to continue its rate hikes.

Via Benzinga

Why Shares of Zai Lab Soared This Week ↗

January 05, 2023

A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗

January 06, 2023

Via Benzinga

Dow Falls Over 200 Points; Walgreens Earnings Top Expectations ↗

January 05, 2023

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 200 points on Thursday.

Via Benzinga

Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 05, 2023

Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 05, 2023

Via Benzinga

Nasdaq Down Over 100 Points; Crude Oil Rises 1% ↗

January 05, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq Composite shedding more than 100 points on Thursday.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

NovoCure Limited - Ordinary Shares (NQ:NVCR)

All News about NovoCure Limited - Ordinary Shares

Starting at $3.75/week.

Subscribe Today